Personal Finance

The 2 Major Catalysts Behind Myriad Genetics, Inc.'s 26% Gain in August

A doctor showing a patient their test results on a tablet.

What happened

Shares of Myriad Genetics (NASDAQ: MYGN) , a leading developer of molecular diagnostic tests, surged by 26% during the month of August, according to data from S&P Global Market Intelligence . Why the sudden surge? The bulk of the gains look traceable to the company's fourth-quarter and full-year earnings release on Aug. 8, as well as positive insurance coverage decisions made on a key diagnostic product mid-month.

So what

The rally really began for Myriad Genetics following the release of its fourth-quarter report. During Q4, Myriad wound up generating $200.5 million in sales, an 8% year-over-year improvement, largely helped by growth in its GeneSight test. Despite the jump in sales, its adjusted profit fell by 17% to $0.30 per share. Nevertheless, Myriad wound up topping Wall Street's sales and profit projections for the fourth quarter. This beat, coupled with growth from newer diagnostic products, which have helped offset competitive weaknesses in its hereditary cancer testing franchise (e.g., BRCA gene tests), clearly have investors upbeat about Myriad's prospects.

A doctor showing a patient their test results on a tablet.

Image source: Getty Images.

The other catalyst driving big gains in August was favorable insurer coverage decisions for EndoPredict, a next-generation prognostic test that helps physicians determine a best course of care for patients with breast cancer. Myriad wound up announcing that Palmetto GBA, the Medicare contractor that oversees the MoIDx (Molecular Diagnostics) program, and Anthem , the second-largest insurer nationally, have decided to cover EndoPredict. Following the implementation of these decisions, Myriad will be able to cover more than 90% of breast cancer patients, which is pretty impressive considering EndoPredict was launched less than six months ago.

Now what

In a world of personalized medicine, Myriad Genetics continues to lead the charge. Unfortunately, this is also an increasingly crowded space that tends to rely on healthy reimbursements from Medicare and Medicaid. With the Trump administration looking to cut long-term payouts to both programs, it leaves Myriad's future somewhat cloudy.

By a similar token, the company has also seen price erosion from competition in its hereditary cancer segment, from which it derives about three-quarters of its sales. However, growth from new products, compounded with volume growth in hereditary cancer testing, even at a lower margin, could still fuel substantial sales and profit improvements in the coming years.

So, what's an investor to do? I'd suggest that modest optimism seems fair at these levels. It's probably going to take a few more years before sales in Myriad's core operating segment level off, but at the same time it should be able to continue to grow its newly launched diagnostic products . Once the company has a more balanced revenue stream, it should be able to throttle back a bit on its operating expenses and allow its operating margin to soar. Patient investors with at least a five-year time horizon should do just fine.

10 stocks we like better than Myriad Genetics

When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*

David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Myriad Genetics wasn't one of them! That's right -- they think these 10 stocks are even better buys.

Click here to learn about these picks!

*Stock Advisor returns as of August 1, 2017

Sean Williams has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy .

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

MYGN

Other Topics

Stocks

Latest Personal Finance Videos

    #TradeTalks: The Changing E-Commerce Landscape

    e-Commerce Consultant James Thomson joins Jill Malandrino on Nasdaq #TradeTalks to discuss the changing e-commerce landscape, what consumers should prepare for as we head into shopping season and why you shouldn’t do last minute shipping.

    9 hours ago

    The Motley Fool

    Founded in 1993 in Alexandria, VA., by brothers David and Tom Gardner, The Motley Fool is a multimedia financial-services company dedicated to building the world's greatest investment community. Reaching millions of people each month through its website, books, newspaper column, radio show, television appearances, and subscription newsletter services, The Motley Fool champions shareholder values and advocates tirelessly for the individual investor. The company's name was taken from Shakespeare, whose wise fools both instructed and amused, and could speak the truth to the king -- without getting their heads lopped off.

    Learn More